Navigation Links
Luminex Corporation Reports Fourth Quarter And Full Year 2015 Results

AUSTIN, Texas, Feb. 1, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the fourth quarter and year ended December 31, 2015.  Financial and operating highlights for the fourth quarter and full year 2015 include the following:

  • Consolidated fourth quarter revenue of $60.4 million, a 4 percent increase compared to the fourth quarter of 2014; full-year 2015 revenue was $237.7 million, a 5 percent increase over 2014.
  • Fourth quarter assay revenue of $26.9 million, a 12 percent increase over the fourth quarter of 2014; full-year 2015 assay revenue of $101.2 million, a 15 percent increase over 2014.
  • Fourth quarter system revenue of $8.5 million, a 24 percent increase over the fourth quarter of 2014; full-year 2015 system revenue of $30.7 million, a 5 percent increase over 2014.
  • GAAP net income for the fourth quarter and full-year of 2015 was $20.4 million and $36.9 million, or $0.47 and $0.86 per diluted share, respectively. Non-GAAP net income for the fourth quarter and full-year 2015 was $24.1 million and $54.5 million, or $0.56 and $1.28 per diluted share, respectively (see Non-GAAP reconciliation).
  • Expanded full-year 2015 operating margins to 16% from 12% in 2014 as a result of both increased revenues and significant expense control.
  • Cash and short and long-term investments at quarter's end totaled approximately $148 million, an increase of approximately $40 million compared with year-end 2014.
  • In December, Luminex announced the Company had received FDA Clearance for NxTAG® Respiratory Pathogen Panel.
  • "In 2015, Luminex achieved all of its major product development and regulatory milestones, including FDA clearances of the NxTAG RPP assay, the ARIES sample to answer molecular system, and the ARIES HSV1&2 assay, as well as our initial goal of placing 30 ARIES systems. We generated solid financial results for the year, achieving record revenue of $238 million, gross margins of 71% and generated over $40 million of cash flow," said Homi Shamir, President and Chief Executive Officer of Luminex. "Moving forward, we will continue to leverage our balanced business model and strong financial position to accelerate future revenue and earnings growth.  In addition, we are focused on executing a successful market introduction of ARIES, which we anticipate will accelerate over time with the expansion of available ASR products and FDA clearance for additional assays. In addition, we continue to make good progress with our next-generation ARIES chemistry and expect to have a first assay enter clinical trials in the second half of 2017. With exciting new products on the market and strong cash flow, we are excited to build on our solid performance in 2015. We look forward to another successful year ahead."REVENUE SUMMARY(in thousands, except percentages) Three Months EndedDecember 31,Variance20152014($)(%)(unaudited)System sales

    $  1,67524%Consumable sales

    10,56810,779(211)-2%Royalty revenue

    9,48910,194(705)-7%Assay revenue

    26,89324,0512,84212%All other revenue

    4,9526,210(1,258)-20%$  60,449$  58,106$  2,3434%Twelve Months EndedDecember 31,Variance20152014($)(%)(unaudited)System sales

    $  30,676$  29,200$  1,4765%Consumable sales

    43,28248,300(5,018)-10%Royalty revenue

    41,51339,4092,1045%Assay revenue

    101,21687,65313,56315%All other revenue


     Additional Financial Highlights:

  • Infectious disease assay sales were approximately 69 percent of total assay sales for the fourth quarter and genetic testing assays were 31 percent.
  • Royalty revenues reflect total royalty-bearing end-user sales for the quarter of $9.5 million.
  • Consolidated gross profit margin was 72 percent for the fourth quarter, and 71 percent for the full year 2015.
  • 263 multiplexing analyzers were shipped during the quarter, which included 78 MAGPIX® systems, 137 LX systems, and 48 FLEXMAP 3D® systems.
  • Days sales outstanding (DSO) was 44 days at quarter-end.

    The Company intends to provide annual revenue guidance, to be updated, as appropriate, at each quarterly reporting period. Guidance for fiscal 2016 is as follows:

  • The Company expects fiscal 2016 revenue to be between $245 million and $255 million.
  • The Company anticipates first quarter 2016 revenue to be between $60 million and $62 million.

    Management will host a conference call at 3:30 p.m. CST/4:30 p.m. EST, Monday, February 1, 2016 to discuss the operating highlights and financial results for the fourth quarter and year ended December 31, 2015. The conference call will be webcast live and may be accessed at Luminex Corporation's website at Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; the development progress of our pipeline products, including ARIES and NxTAG products, market acceptance of our products, including instruments, consumables and assays, regulatory clearance of our products; the ability of our investment in current initiatives and new products to drive long-term value for our shareholders; and, projected 2016 performance, including revenue guidance. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex' products and technology in development, including ARIES and NxTAG products, the uncertainty relating to increased focus on direct sales to the end user, dependence on strategic partners for development, commercialization and distribution of products, concentration of Luminex' revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex' technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges, the timing of and process for regulatory approvals, the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of Luminex' partners and end users and their ability to finance purchases of Luminex' products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of Luminex' assay products, Luminex' ability to obtain and enforce intellectual property protections on Luminex' products and technologies, risks and uncertainties associated with implementing Luminex' acquisition strategy, including Luminex' ability to obtain financing, Luminex' ability to integrate acquired companies or selected assets into Luminex' consolidated business operations, and the ability to recognize the benefits of Luminex' acquisitions, reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, Luminex' ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, changes in principal members of Luminex' management staff, potential shortages, or increases in costs, of components or other disruptions to Luminex' manufacturing operations, competition and competitive technologies utilized by Luminex' competitors, Luminex' ability to successfully launch new products in a timely manner, Luminex' increasing dependency on information technology to enable Luminex to improve the effectiveness of Luminex' operations and to monitor financial accuracy and efficiency, the implementation, including any modification, of Luminex' strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex, and risks relating to Luminex' foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2016 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)December 31,2015December 31,2014(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    Short-term investments

    11,988-Accounts receivable, net

    28,85328,272Inventories, net

    31,25236,616Deferred income taxes

    -12,203Prepaids and other

    8,8878,235Total current assets

    209,526177,020Property and equipment, net

    47,79639,945Intangible assets, net

    52,48256,382Deferred income taxes

    31,82115,400Long-term investments



    3,8533,185Total assets

    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    Accrued liabilities

    15,15214,118Deferred revenue

    4,2124,407Total current liabilities

    27,23230,366Deferred revenue


    4,7244,869Total liabilities

    34,02037,532Stockholders' equity:Common stock

    4242Additional paid-in capital

    321,657309,424Accumulated other comprehensive loss

    (1,296)(744)Retained earnings

    48,13311,272Total stockholders' equity

    368,536319,994Total liabilities and stockholders' equity


     LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedDecember 31,Twelve Months EndedDecember 31,2015201420152014(unaudited)(unaudited)Revenue

    $60,449$58,106$   237,708$226,983Cost of revenue

    17,04315,36569,00167,131Gross profit

    43,40642,741168,707159,852Operating expenses:Research and development

    10,94210,41642,69043,135Selling, general and administrative

    23,02020,94784,76082,785Amortization of acquired intangible assets

    1,4459643,9003,913Restructuring costs

    -229-1,882Total operating expenses

    35,40732,556131,350131,715Income from operations

    7,99910,18537,35728,137Interest expense from long-term debt

    ---(6)Other income, net

    23(11)987(46)Settlement of litigation

    2,000-(5,300)-Income before income taxes

    10,02210,17433,04428,085Income tax expense

    10,35512,6283,81710,958Net income

    $  39,043Net income per share, basic

    Shares used in computing net income per share, basic

    42,24141,74442,09141,558Net income per share, diluted

    Shares used in computing net income per share, diluted




    Related medicine technology :

    1. Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement
    2. Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporations xMAP Technology
    3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 29, 2013
    4. Luminex Corporation Achieves Milestone, Ships 10,000th Instrument
    5. Luminex Corporation Reports Second Quarter 2013 Results
    6. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
    8. Luminex Corporation Reports Third Quarter 2013 Results
    9. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
    10. Luminex Corporation Reports Second Quarter 2014 results
    11. Luminex Is Supporting U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Research Efforts to Control African Ebola Outbreak
    Post Your Comments:
    (Date:10/10/2019)... , ... October 10, 2019 , ... ... Gala Cocktail Reception on Thursday, September 26, at the Westchester Country Club in ... the unwavering support of the organization and its mission. , “In Celebration” featured ...
    (Date:10/8/2019)... (PRWEB) , ... October 09, 2019 , ... “When Seconds ... emotions, frustrations, and the realities of the HEMS world through telling the real stories ... Pilot” is the creation of published author Jay A. Humphrey, an EMS helicopter pilot. ...
    (Date:10/8/2019)... ... October 08, 2019 , ... Respected dentist, Dr. Kenneth ... to enhance his skill and knowledge of dental implant diagnosis, placement and maintenance. ... four-part series of classes that combines in-depth lectures with hands-on workshops. Halfway through ...
    Breaking Medicine Technology:
    (Date:10/11/2019)... ... ... A Topping Out event was hosted today at the construction site of the Southwest ... event celebrated reaching the final height of the structure set to open in the ... in Texas, STA’s facility will be home to an organ recovery center including a ...
    (Date:10/10/2019)... ... October 10, 2019 , ... Santa ... (IT) services for the healthcare industry, has completed the first phase of a ... the Commonwealth of The Bahamas towards a fully integrated health information management system ...
    (Date:10/10/2019)... ... October 10, 2019 , ... In ... 21 was excited to hear the significant results of an independent study presented ... of Nitrosigine®. The clinical study poster entitled “The Acute Effects of Citrulline Malate ...
    (Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... What unique ... and future state of aging and wellness in the nation? That question will be ... Active Aging Conference, Leadership Summit and Expo. The event will take place October 10-12, ...
    (Date:10/8/2019)... ... October 08, 2019 , ... ... majority interest in Advanced Fertility Care (AFC), an advanced reproductive services (RE) facility ... expand the availability of RE services to expectant families throughout Arizona and the ...
    Breaking Medicine News(10 mins):